



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA

BIO-ARTIFICIAL LIVER SUPPORT SYSTEM:
An evaluation of models used in demonstrating or
improving metabolic and clinical efficacy

by
MARTIN NIEUWOUDT



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA

**BIO-ARTIFICIAL LIVER SUPPORT SYSTEM:
An evaluation of models used in demonstrating or
improving metabolic and clinical efficacy**

by Martin Nieuwoudt

**Thesis submitted in fulfillment of a PhD
in Chemical Technology**

**in the Department of Chemical Engineering,
University of Pretoria, Pretoria, South Africa**

**Supervisor: Prof. P de Vaal
Co-supervisor: Prof. S van der Merwe**

BIO-ARTIFICIAL LIVER SUPPORT SYSTEM: An evaluation of models used in demonstrating or improving metabolic and clinical efficacy

ABSTRACT

Acute liver failure (ALF) is a rare but devastating clinical syndrome with multiple causes and a variable course. The mortality rate is high. Orthotopic liver transplantation is the only therapy of proven survival benefit but the limited supply of donor organs, the rapidity of progression and the variable course of ALF limit its use. A need therefore exists for a method to ‘bridge’ patients, that is, provide temporary support, to either the spontaneous regeneration of the innate liver or transplantation. One possibility includes bio-artificial liver support systems (BALSS). This technology is composed of an extracorporeal circulation system incorporating a bioreactor that contains parenchymal liver cells (hepatocytes) to perform the detoxifying, transforming and synthetic properties of a liver. However, the development of a BALSS holds particular challenges. Despite approximately four decades of research, bio-artificial liver (BAL) technology globally remains in a pre-commercial stage. The University of Pretoria (UP) and the Council for Scientific and Industrial Research (CSIR) have developed a BALSS with novel characteristics. These include a computationally optimized radial-flow primary porcine hepatocyte bioreactor perfused with blood plasma, and a perfluorocarbon oxygen carrier which replaces hemoglobin. There are also novel design properties in the circulation system itself. Demonstrating the metabolic and clinical efficacy of a BAL device requires implementing, *in vitro* (cell biology), *in vivo* (animal) and mathematical modeling studies. These studies are a formal necessity but are inherently ‘models’ of the *in vivo* human clinical circumstance. That is, they are limited by their experimentally controlled configuration/s. In investigating these, this thesis firstly provides a foundation by reviewing the clinical and biological context of ALF and BAL technology, then presents and evaluates particular studies/models that have been implemented over several years in the course of the UP-CSIR BAL project. For each section, thoughts and recommendations regarding future work that will facilitate the development of BAL technology are discussed in detail. The thesis is concluded with an evaluation of success and the consensus-agreed requirement of continued research and innovation in the field.

Keywords: acute liver failure, bio-artificial liver, hepatocyte bioreactor cell biology, animal models, compartmental pharmacokinetic models, prognosis modeling, bioprocess monitoring, state estimator.

BIO-KUNSMATIGE LEWER ONDERSTEUNINGSTELSEL: ’n Evaluasie van modelle wat gebruik is in die demonstrasie of verbetering van metaboliese en kliniese doeltreffendheid

SAMEVATTING

Akute lewerversaking (ALV) is ’n seldsame maar vernietigende kliniese sindroom met veelvuldige oorsake en uiteenlopende nagevolge. Die sterftesyfers is hoog. Leweroorplanting is die enigste terapie met bewese oorlewingsvoordele, maar die tekort aan oorplantingsorgane en die verskeie nagevolge van ALV beperk die gebruik daarvan. Daar is dus ’n behoefte aan ’n ‘oorbruggingsmetode’, om pasiënte te ondersteun terwyl spontane regenerasie van die bestaande lewer kan plaasvind, of voordat ’n leweroorplanting gedoen word. Een so ’n moontlikheid is ’n bio-kunsmatige lewerondersteuningstelsel (BKLOS). Hierdie tegnologie is ’n buiteliggaamlike sirkulasiestelsel insluitende ’n bioreaktor wat lewerselle (hepatosiete) bevat wat die suiwering, transformasie en sintese eienskappe van die lewer vervul. Die ontwikkeling van ’n BKL-ontwerp hou definitiewe uitdagings in. Ten spyte van vier dekades se internasionale navorsing, bly bio-kunsmatige lewer tegnologie in ’n pre-kommersiële stadium. Die Universiteit van Pretoria (UP) en die Wetenskaplike en Nywerheidsnavorsingsraad (WNNR) het ’n BKLOS met uitsonderlike kenmerke ontwikkel. Dit sluit in ’n rekenaar-geoptimeerde radiaal-vloei primêre vark-hepatosiet bioreaktor wat deurentyd gevul word met bloedplasma en ’n perfluorostikstof suurstofdraer wat hemoglobien vervang. Die sirkulasiestelsel self het ook unieke ontwerpeienskappe. Die demonstrasie van die metaboliese en kliniese doeltreffendheid van ’n BKL-ontwerp vereis die implementering van *in vitro* (selbiologie), *in vivo* (diere) en wiskundige modeleringstudies. Alhoewel sulke studies noodsaaklik is, is hulle inherent ‘modelle’ van die *in vivo* menslike kliniese omstandigheid. In hierdie proefskrif is eerstens ’n basis gebou deur die kliniese en biologiese samehang van ALV en BKL tegnologie te ondersoek. Daarna stel dit voor en evalueer spesifieke studies/modelle wat oor verskeie jare in die loop van die UP-WNNR BKL projek geïmplementeer is. Na elke afdeling is voorstelle bespreek in verband met toekomstige werk wat die ontwikkeling van BKL tegnologie sal vergemaklik. Die proefskrif word afgesluit met ’n evaluering van suksesse tot op datum asook behoeftes aan voortgesette navorsing en ontwikkeling in die veld.



CONTENTS	PAGE
Abstract	iii
Samevatting	iv
List of Figures and Tables	v
Terms and abbreviations	viii
1 INTRODUCTION	1
1.1 Background	1
1.2 Defining <i>Models</i>	3
1.2 Problem statement	4
1.3 Thesis structure	4
1.4 Copyright and authorship issues	6
2 THE CLINICAL AND BIOLOGICAL BACKGROUND OF ACUTE LIVER FAILURE AND LIVER SUPPORT TECHNOLOGY	8
2.1 Introduction	8
2.2 Defining ALF	8
2.3 Epidemiology and etiology	9
2.4 Pathogenesis and the clinical syndrome	10
2.4.1 Hepatic encephalopathy	11
2.4.2 Cerebral edema	13
2.4.3 Coagulopathy	14
2.4.4 Metabolic abnormalities	14
2.4.5 Renal Failure	15
2.4.6 Multi-organ failure	16
2.5 Prognostic scoring systems	16
2.6 Orthotopic Liver Transplantation	18
2.7 Liver support systems	19
2.7.1 Non-biological liver support	20
2.7.2 Biological liver support	21
2.7.3 Biological principles in the design of BAL devices	24
2.7.3.1 Cell type, source and mass	24
2.7.3.2 Cellular oxygenation	27

2.7.3.3	Cell support matrices	28
2.7.3.4	Flow rates, exchange rates and the priming volume	29
2.7.3.5	Detoxification devices and multiple optimized bioreactors	30
3	THE DESIGN OF THE UP-CSIR BALSS	32
3.1	Bioreactor optimization	32
3.2	Circulation system optimization	35
4	<i>IN VITRO</i> CELL BIOLOGY STUDIES overview	42
4.1	A large scale automated method for hepatocyte isolation	43
4.1.1	Introduction	43
4.1.2	Materials and Methods	43
4.1.3	Results	51
4.1.4	Discussion	55
4.2	A study to determine hepatocyte function in the UP-CSIR radial-flow bioreactor using a perfluorocarbon oxygen carrier	57
4.2.1	Introduction	57
4.2.2	Materials and Methods	58
4.2.3	Results	60
4.2.4	Discussion	63
4.3	Imaging glucose metabolism in hepatocyte-stellate co-culture bioreactors using positron emission tomography	67
4.3.1	Introduction	67
4.3.2	Materials and Methods	69
4.3.3	Results	75
4.3.4	Discussion	81
4.4	Thoughts and recommendations	84
4.4.1	Developments in cell sources	85
4.4.1.1	Genetically engineered swine	85
4.4.1.2	Chimeric animals	86
4.4.1.3	Concerns regarding other cell types	87

5	<i>IN VIVO</i> ANIMAL STUDIES overview	90
5.1	Non-toxicity of IV injected perfluorocarbon oxygen carrier in an animal model of liver regeneration following surgical injury	91
5.1.1	Introduction	91
5.1.2	Materials and Methods	92
5.1.3	Results	95
5.1.4	Discussion	101
5.2	Standardization criteria for an ischemic surgical model of acute hepatic failure in pigs	103
5.2.1	Introduction	103
5.2.2	Materials and Methods	104
5.2.3	Results	107
5.2.4	Discussion	114
5.3	Thoughts and recommendations	119
5.3.1	Clinical evaluation of the BALSS using the ischemic model	119
5.3.2	Alternate animal models of ALF	126
5.3.3	Ammonia metabolism, measurement and reduction strategies	128
5.3.4	Which artificial toxin clearance system?	132
6	MATHEMATICAL MODELING STUDIES overview	135
6.1	A pharmacokinetic compartment model of the UP-CSIR BALSS	136
6.1.1	Introduction	136
6.1.2	Materials and methods	137
6.1.3	Data	137
6.1.4	Results	138
6.1.5	Discussion	143
6.2	Developing an <i>on-line</i> predictive clinical monitoring system for acute liver failure patients	147
6.2.1	Introduction	147
6.2.2	Methods	148
6.2.2.1	Data processing	148

6.2.2.2	Conceptual (system) modeling	149
6.2.2.3	Numerical modeling	154
6.2.3	Results	156
6.2.3.1	Class associations	156
6.2.3.2	Quantification of states	156
6.2.3.3	The PI equations	158
6.2.3.4	First-order assumptions	159
6.2.3.5	The BI equations	159
6.2.3.6	Model sensitivity	162
6.2.3.7	Assumptions of normality	162
6.2.3.8	Factors affecting BI accuracy	163
6.2.4	Model Verification	163
6.2.4.1	ANOVA	163
6.2.4.2	Relative error	164
6.2.4.3	Comparison with prospectively acquired <i>un-trained</i> BALSS treatment data	165
6.2.5	Discussion	167
6.3	Thoughts and recommendations	175
6.3.1	Refining prognostic models	176
6.3.2	Non-linear and multivariate regression experiments	176
6.3.3	A UML meta-model to combine the state estimator and the pharmacokinetic model	178
6.3.4	Additional notes on bioprocess monitoring systems	181
7	SUMMARY AND CONCLUSION	185
8	REFERENCES	189
9	APPENDICES	206
	Appendix A: <i>In vitro</i> study methods	206
	Appendix B: <i>In vivo</i> study methods	210
	Appendix C: The derivation of the compartmental model equations	213
	Appendix D: <i>On line</i> model sensitivity and verification	221
	Acknowledgements	236

LIST OF FIGURES	PAGE	
3.1	First iteration, non-flow optimized bioreactor	33
3.2	CFD model of velocity contours of a plasma-PFC mixture over the PUF cell aggregation matrix in the non-optimized bioreactor configuration	33
3.3	Optimized bioreactor design.	34
3.4	CFD model of velocity contours of the plasma-PFC mixture over the PUF cell aggregation matrix in the optimized bioreactor configuration	35
3.5	Schematic of the UP-CSIR BALSS	36
3.6	The BALSS mark I system	37
3.7	Annotated image of the UP-CSIR mark II BALSS	38
3.8	Graphical user control interface for the mark II model	39
3.9	Intensive care unit in the evaluation of the mark II BALSS	40
3.10	Animal undergoing a BALSS treatment	40
4.1.1	Schematic of Perfusion Apparatus	45
4.1.2	Oxygenation flask	46
4.1.3	The BRAT machine	48
4.1.4	Disposable BRAT apparatus	48
4.1.5	BRAT bowl	49
4.1.6a	BRAT Bowl prior to addition of Percoll	50
4.1.6b	BRAT Bowl after addition of Percoll	50
4.1.7	Flow Cytometry: DNA profile after BRAT procedure with and without oxygenation and prior to culturing	54
4.1.8	Flow Cytometry: DNA profile after 3 and 7 days culturing	54
4.2.1	Simplified <i>in vitro</i> dynamic model of the BALSS	59
4.2.2	SEM image of open-cell PUF cell adhesion matrix with cell aggregations	61
4.2.3	SEM Image of a single large cell aggregate in the PUF adhesion matrix	62
4.2.4	^{99m} Tc-DISIDA isotope scan of PUF cell aggregation matrix.	62
4.2.5	Increased PFOB volume fraction increases the oxygen carrying capacity of emulsions	65
4.2.6	Simulation of bioreactor O ₂ requirements	66
4.3.1	The dual bioreactor <i>in vitro</i> model/s of the BALSS	72
4.3.2	CT and PET scan of hypoxic gas mix cell-seeded bioreactor without PFC	78
4.3.3	CT and PET scan of hypoxic gas mix cell-seeded bioreactor with PFC	79
5.1.1	Liver regeneration projections, assuming linear re-growth	98
5.2.1	Magnitude of correlations of absolute values of systemic indices during surgery [T<0] with duration of survival	112
5.2.2	Magnitude of correlations of biochemical trends following surgery (T>0) with duration of animal survival	113
6.1.1	Compartmental diagram of the BALSS system connected to a patient	137
6.1.2	BALSS sub-circulation concentration profiles for ammonia	139
6.1.3	The influence of bioreactor cell loading on ammonia accumulation	140
6.1.4	Influence of blood exchange rate on ammonia accumulation in the patient	141
6.1.5	The influence of the clearance to production ratio on blood ammonia concentration	142
6.1.6	Variation in reported values of ammonia clearance	145
6.2.1	Class diagram for data attributes of the patient-ALF-system	150
6.2.2	A system state transition diagram for the ALF-patient system	153

6.3.1	UML meta-model of the combined ALF-patient-BALSS compartment models	180
6.3.2	UP-CSIR BALSS FI sampling manifold with ion-specific electrodes	183
D.2.1	Linearity of variable trends	223
D.3.1	Tornado diagram for PI model (T<0)	224
D.3.2	Tornado diagram for PI model (T>0)	225
D.3.3	BI Model Sensitivity for BcAA/AroAA (BI)	225
D.3.4	BI Model sensitivity for creatinine	226
D.3.5	PI Model (T<0) prediction variation using normal distributions of independent variables	227
D.3.6	PI Model (T>0) prediction variation using normal distributions of independent variables (T>0)	227
D.3.7	PI Model (T>0) prediction variation using uniform distributions of non-Gaussian variables	228
D.6.2.1	Relative prediction error for the PI (T<0)	233
D.6.2.2	Relative error for PI (T>0)	233
D.6.2.3	Relative error for the BI (Prothrombin time)	234
D.6.2.4	Relative error for the BI [BcAA/AroAA]	234

LIST OF TABLES

2.1	Grade scale for hepatic encephalopathy	12
2.2	Some historically commonly used prognostic criteria for ALF	17
2.3	Summary of non-biological and biological liver support systems	19
2.4	System characteristics and outcomes of clinical trials	23
2.5	The advantages and disadvantages of various cell sources for BAL's	25
2.6	The relative advantages and disadvantages of culture configurations	29
4.1.1	Yield and viability of hepatocytes per liver, following isolation using Centrifuge and BRAT technology	52
4.2.1	Variation in results for porcine hepatocytes	64
4.3.1	PET counts (FDG-uptake) and blood gas results at 24 hours post isolation	77
4.3.2	Steady state biochemistry at 24 hours post isolation	80
4.4.1	Simple accounting of expense differences for primary and transformed cells	88
5.1.1	The experimental sub-groups	93
5.1.2	Measured variables and units	95
5.1.3	Weight changes, biochemistry and haematology	96
5.2.1	Measured variables	108
5.2.2	Values of measured variables	109
5.2.3	Standardization criteria for a porcine surgical (ischemic) model of AHF	116
5.3.1	Record of large animal experiments	121
5.3.2	Definition of variables and units	122
5.3.3	Comparison between BALSS treated and non-treated animals	123
5.3.4	Control and experimental groups in animal trials	128
6.2.1	Attributes (clinical variables) for the class diagram	151
6.2.2	Examples of state and sub-state definitions	157
6.2.3	Model equations and weights for the PI	158
6.2.4	Variable candidates for the BI	160
6.2.5	BI model equations	161



6.2.6	Comparison of predicted to actual BALSS test data with the PI	166
6.2.7	Review of variables that have demonstrated prognostic value in ALF	169
6.2.8	Examples of commercially available FI systems	173
6.3.1	Differences between the state estimator and the compartmental model	179
A.4.1	Modified-HGM cell culture media components	209
D.1	Numerical associations in and between classes	221
D.4.1	Normality of independent variables in the PI	229
D.5.1	The independent variables used to calculate each biochemical in the BI	230
D.6.1	ANOVA results for the PI and BI model/s	231
D.6.2.1	Comparative accuracy of the PI and BI models (using ‘trained’ data)	235

LIST OF TERMS AND ABBREVIATIONS

The majority of definitions were taken from the *on-line* medical dictionary of the University of Newcastle Upon Tyne (available at <http://cancerweb.ncl.ac.uk/omd/>).

Term	Meaning
<i>a priori</i>	previously defined or assumed (facts)
acidosis/ alkalosis	a metabolic condition, characterized by an increase or decrease in hydrogen ion concentration
allocompatibility	immunological compatibility of substance/fluid from another person or organism
average relative accuracy/error region	the product of the measurement range and the standard deviation of the relative error (see below)
bioanalytical/bioprocess monitoring system	a (typically) predictive, <i>on-line</i> monitoring system for a contained biological process (normally for commercial purposes)
biochemical	a molecule characterized or produced by chemical reactions in a living organism
bioreactor	a closed device housing cells used for generating/metabolizing biological substances
bioresorbable	a material that may be metabolized/absorbed when inserted into an organism's tissues
biosensor	a sensor for particular biological stimuli in a bioprocess
bio-systems model	a computational representation of a biological system or bioprocess
boolean switching net	a network of switches employing Boolean rules
bootstrapping	a statistical method for generating theoretical data where limited or no measured data is available
cardiac arrhythmia	an irregular electrical pattern of cardiac activity
cell aggregation/support matrix	a synthetic or biological three dimensional matrix into which aggregation dependent cells are seeded
chemokine	cytokines that are chemotactic for leucocytes (e.g. IL-6)
disseminated intravascular coagulopathy	a complication of septic shock where endotoxin induces systemic blood clotting, depletion of coagulation factors and thrombocytopenia leading to widespread spontaneous bleeding.
chemotactic	the responsiveness of motile cells to concentration gradients of particular dissolved substances
cytokines	small molecules released by cells and having specific effects on cell-cell interaction, communication and behaviour (e.g. IL-1 β)
data driven modeling	modeling procedures based on empirically observed (rather than theoretical) trends in measured data
devascularization	surgical occlusion or all or most of the blood vessels to an organ or tissue
endotoxin	toxic membrane lipopolysaccharides of gram negative bacteria
epileptiform activity	brain electrical activity normally associated with epileptic seizures
etiology	a branch of medical science concerned with the



flow injection analysis	causes or origins of diseases the analysis of a chemical substance by removing a sample from a flow stream and mixing it with a reagent to produce a measurable reaction for a detector and subsequent data logging device
gluconeogenesis	the synthesis (mainly by the liver) of glucose from non-carbohydrate precursors
genotype	the total genetic constitution of a cell or organism
glomerular filtration	filtration function performed by the glomerular cells of the kidney
glycolysis	the anaerobic conversion of glucose to pyruvate
haemodynamic	relating to physical aspects of the blood circulation
hepatectomy	the surgical removal of the liver
hepatocytes	the epithelial cells composing (approximately) 80% of the liver
hepatotoxic	toxic to the liver
hepatotrophic	causing liver growth or regeneration
hyper/hypocapnia	an excess or deficiency in carbon dioxide in the blood resulting from hypo or hyper ventilation and leading to acidosis or alkalosis respectively
hyper/hypoglycemia	an excess or deficiency of glucose in the blood
hyper/hypokalemia	an excess or deficiency of potassium in the blood
hyper/hypometabolic	an excess or deficiency in metabolic activity
hyper/hyponatremia	an excess or deficiency of sodium in the blood
hyper/hypophosphatemia	an excess or deficiency of phosphate in the blood
hyper/hypotension	persistently high or low arterial blood pressure
hyper/hypovolemia	increased or decreased blood volume
hyperammonemia	a pathologically increased blood ammonia concentration
hypoxic	a lack of oxygen (low pO ₂)
immunosuppression	the suppression of T or B lymphocytes with particular drugs
<i>in situ</i>	in a natural or normal bodily compartment without entering any other place
<i>in silico</i>	a computer-based simulation or model of a system
<i>in vitro</i>	observable in an artificial environment (e.g. a laboratory)
<i>in vivo</i>	within a living body
ischemic	a lacking in oxygen supply to the organs commonly due to a decrease in blood perfusion
Kalman filter	a linear bioprocess observer used to reconstruct the state of a system (including the estimation of non-measurable variables) and to decrease measurement noise. It has time varying observer gain and the descriptive equations are a linear combination of ordinary differential equations.
knowledge-based	a system incorporating clinical knowledge
laparotomy	general abdominal surgery
leucocyte	a member of the group of white blood cells
linearization	a mathematical procedure by which a (non-linear) function is estimated in terms of the expansion of its derivatives at a point of interest
lipohylic/phobic	lipid/fat soluble or insoluble



mass transfer	the concentration gradient of a particular substance at a defined interface
metabolic zonation	the ability of tissues within an organ to adapt to different metabolic requirements
microdialysis	very low volume flow injection method for analyzing biological fluids
mitogenic	the ability of a substance to induce mitosis (division) in eukaryotic cells i.e. growth or regeneration
model	an experimentally controlled simulation of an objective system, circumstance or reality.
model standardization	the reduction of a complex system to particular criteria or rules determining its validity or success
monte carlo analysis	a statistical method in which (bound) random data is generated to overcome limitations in the amount of measured data available (see 'bootstrapping')
necrosis	a form of cell death
nephrotoxic	toxic to kidneys
object oriented model	a model in which the functional units of a system are defined as objects having characteristics that are definable using particular computational methods (e.g. the UML)
Occam's razor	The principle, by which particular predictions of a model are excluded, based on their not being observed in reality. Alternately, 'the simplest explanation is the best'
<i>off-line</i>	not measurable at the time at which a process takes place i.e. results are only available subsequently
<i>on-line</i>	measurable at the time at which a process takes place so that results may potentially be input into a control system
parenchymal/non parenchymal	tissues/cells composing (or not composing) the general functional framework or stroma of an organ
perfusate	a body fluid perfusing a particular stream in a system (e.g. a plasma perfused bioreactor)
periportal	surrounding or close to the intrahepatic portal vein branches (i.e. high oxygen content blood at the inlet of the liver)
perivenous	surrounding or close to the central vein (i.e. low oxygen content blood at the outlet of the liver)
petri net	describes a process in terms of places (circles), transitions (rectangles) and arcs (lines). The formal mathematical semantics used to define discrete distributed systems
pharmacokinetic compartmental model	a closed system of physiological compartments between which the mass transfer (production or clearance) of particular substances may be described using ordinary differential equations (i.e. as defined by Michaels-Menten kinetics)
phenotype	the expressed functional characteristics of a cell or organism resulting from the interaction of its genotype to particular environmental conditions
point error	the difference between corresponding predicted to measured values as a fraction of each measured value



prognostic criteria	particular rules or metabolic indices that may be used to forecast the probable outcome of a clinical intervention or disease process
prophylaxis	preventive treatment for a disease
<i>real-time</i>	synonymous with <i>on-line</i> i.e. data measurable during an experiment or procedure
relative error	a percentile value for the point error divided by the standard deviation of the measured population
software sensor	an indirect computational method for estimating a non-measurable process variable
spectrophotometric detection	a method for determining biochemical concentrations in a sample based on the absorbance/transmission of light at particular wavelengths
splanchnic circulation	blood circulation to the internal organs and lower limbs
state estimator	a system which produces estimates of measurable and non-measurable state variables in a bioprocess
state machine/diagram	a UML graphical representation of the behaviour of a system i.e. the total set of states and transitions through which the system may proceed
stellate cell	Star-shaped, non parenchymal cells in the liver facilitating the phenotypic stabilization of hepatocytes during liver regeneration
systemic	pertaining to the integrated functions of the body as a whole
tornado diagram	a diagram displaying the sensitivity of the outputs of a model in term of its inputs
tumorigenic	tendency to cause cancer
vasoconstriction/dilation	the diminution/enlargement of vascular diameters (especially arterioles) leading to a decrease or increase in blood perfusion to tissues/organs downstream
xenogenic	originating from outside and introduced into an organism (i.e. a foreign material)
zoonosis	the transmission of a disease from an animal or non-human species to a human

Abbreviation	Meaning
ABG	arterial blood gas
ABP	arterial blood pressure
AHF	acute hepatic failure (synonymous with acute liver failure)
ALF	acute liver failure
AMC-BAL	Amsterdam Medical College bio-artificial liver
ANN	artificial neural network
ANOVA	analysis of variance
ARDS	acute respiratory distress syndrome
BAL	bio-artificial liver
BALSS	bio-artificial liver support system
BLSS	bio-artificial liver support system
CE	cerebral edema

CFD	computational flow dynamics
CPP	cerebral perfusion pressure
CSIR	Council for Scientific and Industrial Research
CVP	central venous pressure
CVVHDF	continuous veno-venous hemodiafiltration
DIC	disseminated intravascular coagulopathy
ECG	electrocardiogram
EEG	electroencephalogram
EGF	epidermal growth factor
ELAD	extracorporeal liver assist device
FDA	US federal drug administration
FHF	fulminant hepatic failure
GCP	good clinical practice
GFR	glomerular filtration rate
GMP	good manufacturing practice
GUI	graphical user interface
HAL	hepatic artery ligation
HBAL	hybrid bio-artificial liver
HBV	hepatitis B virus
HE	hepatic encephalopathy
HGF	hepatocyte growth factor
HIV	human immuno virus
HRS	hepato-renal syndrome
ICP	intracranial pressure
IL-1 β	interleukin-1beta
IL-6	interleukin six
INR	international normalized ratio
IVC	inferior vena cava
K _m	Michaelis constant
MAP	mean arterial pressure
MARS	molecular adsorbents recirculation system
MCA	monte carlo analysis
MELS	modular extracorporeal liver support
MEM	minimum essential medium
MOF	multi-organ failure
NAC	N-acetylcysteine
NO	nitric oxide
OLT	orthotopic liver transplantation
OUR	oxygen uptake rate
PCA	porto-caval anastomosis
pCO ₂	partial pressure of carbon dioxide
PET	positron emission tomography
PERV	porcine endogenous retrovirus
PFC	perfluorocarbon
PFOB	perfluorooctyl bromide
pO ₂	partial pressure of oxygen
PROM	Prometheus artificial liver support system
PT	prothrombin time
PUF	polyurethane foam
RFB	radial flow bioreactor
SFHF	subfulminant hepatic failure
SIRS	systemic inflammatory response syndrome



SOM	self organizing map
TECA-HAL	TECA-hybrid artificial liver support system
TGF- α	transforming growth factor alpha
TNF- α	tumour necrosis factor alpha
UML	unified modeling language
UP	University of Pretoria
UPBRC	University of Pretoria Biomedical Research Centre
V_{\max}	Michaelis-Menten kinetics V max value